F.D.A. Urges Release of Missing Trial Data

TL;DR

F.D.A. sent over 2,200 letters urging drug developers, device makers, and researchers to publish unreported clinical trial results.
About 30 percent of studies have failed to report results on ClinicalTrials.gov despite legal requirements.
Unreported negative results skew treatment data, harming doctors' ability to choose effective drugs.

The story at a glance

The Food and Drug Administration announced it sent more than 2,200 letters to drug manufacturers, medical device makers, and researchers pressing them to submit unpublished clinical trial data. F.D.A. Commissioner Dr. Marty Makary called it a public health issue because companies often suppress unfavorable results. The action follows an internal analysis showing widespread noncompliance with reporting rules, timed with Monday's announcement.

Key points

Drug developers must post results on ClinicalTrials.gov within a year of trial completion, but an F.D.A. review found roughly 30 percent of applicable studies unreported.
The letters request voluntary compliance rather than immediate penalties like daily fines over $10,000 or funding cuts by the National Institutes of Health.
Dr. Makary said companies have a "moral duty" to report, as hidden negative data makes it hard for physicians to pick the best treatments.
Critics like Christopher Morten of N.Y.U. School of Law call the effort "more symbolic than substantive," noting a 2023 petition for tougher enforcement.
Holly Fernandez Lynch of the University of Pennsylvania stressed that reporting is a "critically important scientific and ethical requirement."

Details and context

Companies skip reporting negative results because they look bad for marketing, leaving doctors with incomplete data on drug risks and benefits. This has long been a concern; laws require posting summaries on ClinicalTrials.gov to build a full picture of evidence.[[1]](https://www.nytimes.com/2026/04/13/well/fda-clinical-trials.html?gaa_at=g&gaa_n=AWEtsqfffkJUydNcZWrMmf-jmHP9u1eCQhEniY_T2ffwsSwtNUqDOzoK4nqHb06rZvWOqjxB1rbi2cM5ZyCF21RAvfCT&gaa_ts=69ddd799&gaa_sig=y0mkVhlIQTAgSdxINdoZP7L36gQE5NemnvdbMOE1tKImJk1nUGHgzDo0CJTaZ8QJFkw_yIcKTv7tLalwtb-RLA==)[[2]](https://www.nytimes.com/2026/04/13/well/fda-clinical-trials.html)

The F.D.A. chose letters over fines to encourage cooperation, but experts say enforcement has been weak for years. Past efforts, like Morten's petition, pushed for automatic penalties to fix the gap.

Key quotes

Dr. Marty Makary, F.D.A. commissioner: “What I want to see is companies do the right thing and realize the moral duty they have.”
Dr. Marty Makary: “It’s a public health issue.”

Why it matters

Unreported trial data distorts medical evidence, leading to overuse of risky or weak drugs and underuse of better ones. Doctors and patients face concrete risks from skewed information when choosing treatments, while drug companies avoid scrutiny on failures. Watch if companies comply or if the F.D.A. imposes fines, as future enforcement could set stricter standards.